Persistent URL of this record https://hdl.handle.net/1887/113304
Documents
-
- Download
- 10.1136_annrheumdis-2016-209709
- Not Applicable (or Unknown)
- open access
In Collections
This item can be found in the following collections:
Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1
- All authors
- Mease, P.J.; Heijde, D. van der; Ritchlin, C.T.; Okada, M.; Cuchacovich, R.S.; Shuler, C.L.; Lin, C.Y.; Braun, D.K.; Lee, C.H.; Gladman, D.D.; SPIRIT-P1Study Grp
- Date
- 2017-01-31
- Journal
- Annals of the Rheumatic Diseases
- Volume
- 76
- Issue
- 1
- Pages
- 79 - 87